New Trends in Vaccine Development

 In News

BV Science, through a presentation by its scientific director, Ph.D. Sherry Layton, will participate in the Global Conference on Vaccines Research and Development, which will be held online on August 26 and 27.

BV Science, the Vetanco S.A. and Dr. Bata Ltd. company in the US, will be present at the Global Conference on Vaccines Research and Development, an online seminar to be held on August 26 and 27. There, Ph.D. Sherry Layton, Scientific and Biological Director at Vetanco and BV Science will give a talk entitled “New Trends in Vaccine Development.” The presentation will be held on the second date.

Notably, Dr. Sherry Layton received her Ph.D. from the University of Arkansas (USA), where she studied Poultry Science. Her early career research in poultry immunology and molecular engineering laid the foundation for her pioneering scientific successes in animal health. During the last decade, Dr. Layton developed and patented an innovative oral subunit vaccine platform, Biotech Vac. This research and development led to the recent groundbreaking introduction of Biotech Vac – Salmonella in South America, which provides poultry with immune protection against all mobile Salmonella species, a breakthrough in the poultry industry that will help reduce the risk of foodborne illnesses such as salmonellosis in humans.

As an expert in poultry vaccines, Dr. Layton conducts numerous academic and industry conferences around the world. Currently, as Scientific and Biological Director at Vetanco and BV Science, she leads a research team of veterinarians and scientists in the US and Argentina, and has developed a line of pioneering and effective vaccines. She collaborates in the introduction of Biotech Vac – Salmonella in Argentina and Brazil, as well as in the establishment of biological products in the US market through Vetanco USA.

“The response to the COVID-19 pandemic has seen an unprecedented explosion in R&D, cooperation and collaboration. We see new ideas, new approaches, and new vaccines. The global pace is impressive!,” highlights Dr. Daniel R. Henderson, Chairman of Vaccines Conference-2021 and CEO & CSO – Verndari, Inc, USA.

“The past 2 years have redefined our global approach to pandemic preparedness and solution deployment. Vaccines, more than any other approach, have been at the center through the innovations and failures we have witnessed. This has challenged current approaches to vaccines at all levels (…), but also opens up a realm of possibilities for the future of vaccines and vaccination,” adds Dr. Nathalie Garcon, VP of the Vaccines Conference-2021 and CEO/CSO-BIOASTER, France.

For more information on the presentation, please visit:


Recommended Posts

Leave a Comment

Start typing and press Enter to search